Jacobs Levy Equity Management Inc. Decreases Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Jacobs Levy Equity Management Inc. lowered its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 18.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 414,120 shares of the medical instruments supplier’s stock after selling 95,157 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in AngioDynamics were worth $3,222,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ANGO. Quarry LP lifted its stake in shares of AngioDynamics by 75.1% in the 2nd quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 2,594 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in AngioDynamics by 9.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 33,772 shares of the medical instruments supplier’s stock worth $199,000 after buying an additional 2,821 shares during the last quarter. CWM LLC boosted its stake in AngioDynamics by 981.3% during the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after buying an additional 8,832 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in AngioDynamics during the third quarter valued at $86,000. Finally, Charles Schwab Investment Management Inc. increased its position in AngioDynamics by 3.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 326,820 shares of the medical instruments supplier’s stock valued at $2,543,000 after acquiring an additional 11,599 shares during the last quarter. 89.43% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Canaccord Genuity Group lowered their target price on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a report on Friday, October 4th. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of AngioDynamics in a research note on Friday, October 4th.

AngioDynamics Stock Down 1.4 %

ANGO stock opened at $7.00 on Friday. The firm has a market cap of $284.44 million, a price-to-earnings ratio of -1.15 and a beta of 0.68. AngioDynamics, Inc. has a twelve month low of $5.26 and a twelve month high of $8.25. The business’s fifty day simple moving average is $6.84 and its two-hundred day simple moving average is $6.85.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. The company had revenue of $67.50 million during the quarter, compared to analyst estimates of $67.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The firm’s revenue for the quarter was down 14.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.12) EPS. Research analysts expect that AngioDynamics, Inc. will post -0.41 EPS for the current year.

Insider Activity at AngioDynamics

In other news, CEO James C. Clemmer bought 20,000 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was acquired at an average cost of $6.03 per share, with a total value of $120,600.00. Following the transaction, the chief executive officer now directly owns 681,582 shares in the company, valued at approximately $4,109,939.46. This trade represents a 3.02 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders bought 22,568 shares of company stock worth $135,847. Company insiders own 5.40% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.